Cargando…
A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
Acute lymphoblastic leukemia (ALL) is a hematologic cancer that begins in the bone marrow and results in an overproduction of lymphocytes. It can present as palpable purpura, which is also seen in many other pathologies, including vasculitides such as IgA vasculitis. We present a case of a 52-year-o...
Autores principales: | DeRon, Nathan, Jivraj, Sereena, McCreight, Hannah, Permann, Austin, Oluwadamilola, Babaniji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872561/ https://www.ncbi.nlm.nih.gov/pubmed/36699758 http://dx.doi.org/10.7759/cureus.32921 |
Ejemplares similares
-
Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
por: Tanneeru, Karunakar, et al.
Publicado: (2013) -
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018) -
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007) -
Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022) -
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)